BioWorld

Feb. 24, 2003

Monitoring Committee Suspends Enrollment In QLT, Xenova Trial

QLT Inc. agreed to temporarily suspend enrollment in two Phase III studies of tariquidar in non-small-cell lung cancer patients on advice of a monitoring committee, which reportedly noted some toxicity in the study. (BioWorld Today) Read More

BioMarin Raises $75M Publicly, Gets Good News On Aldurazyme

Two Interleukin Molecules, IL-12 & IL-23, Duke It Out To Nail Guilt Or Innocence In Mouse Autoimmunity

Nasdaq Market Looking To Ease Rules For Continued Listing

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for July 6, 2026.

CINP 2026: Prenatal and adolescent stress shape brain vulnerability

BioWorld Science

Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...

Ontrack Therapeutics divulges compounds for neurodegenerative diseases

BioWorld Science

Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

Neuracle eyes Shanghai IPO as global BCI funding surges

BioWorld

Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...